We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Projects granted during 2015 that have a primary purpose of basic research: musculoskeletal system.
Projects granted during 2014 that have a primary purpose of basic research into the musculoskeletal system.
Projects granted during 2014 that have a primary purpose of translational and applied research: human musculoskeletal disorders.
Advice for medical professionals to follow when assessing drivers with neurological disorders.
Volume 20 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
Globally, there has been a very small number of reports of new-onset or aggravation of pre-existing myasthenia gravis with atorvastatin, pravastatin, lovastatin, fluvastatin, simvastatin, rosuvastatin and pitavastatin (single-ingredient and fixed-dose combination products). Advise patients taking statins to be alert to...
Read about talking therapies and counselling for mental health problems.
Find out about coronavirus (COVID-19) treatments available outside of hospital, including information on free prescriptions and lateral flow tests.
DHSC publications relating to COVID-19 treatments and clinical trials.
Collection of documents relating to COVID-19 treatments.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (7 March 2024) approved the medicine rozanolixizumab (Rystiggo) to treat adults with generalised myasthenia gravis, an autoimmune disease that causes muscle weakness, which can affect multiple muscle groups throughout the...
Explains how commissioners and health professionals can use data and analysis for decisions about neurology services and interventions.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Department of Health response to Raj Long’s independent report on the challenges faced when developing treatments for dementia.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.